SEC to review Bharat Bio's intranasal jab for use as booster soon

Covaxin - and has submitted the data to the Drugs Controller General of India (DCGI) for the review. Hyderabad based Bharat Biotech has sought market authorisation approval from Drugs Controller General of India (DCGI) for their intranasal heterologous booster in the 5-18 age group.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5xXIylA
via IFTTT